The EMBER trial, a multicenter, open-label phase Ia/b dose-escalation/expansion trial, included patients with ER+ advanced breast cancer (prior endocrine therapy sensitivity; ≤3 prior therapies for advanced breast cancer). This evidence concerns the gene ESR1 and breast cancer.